Highest-materiality recent filing
Definitive Healthcare receives Nasdaq bid-price deficiency notice; has until Dec 15, 2026 to comply
Nasdaq notified Definitive Healthcare on June 18, 2026 that its stock failed to meet $1.00 minimum bid price for 30 consecutive days.
Definitive Healthcare shareholders approve 15M share increase under 2021 equity plan
Amendment to 2021 Equity Incentive Plan approved: shares authorized increase from 30.97M to 45.97M (15M new shares).
Definitive Healthcare Q1 revenue $55.9M (-6% YoY); net loss $192.4M on $197M goodwill impairment
Revenue of $55.9M, at top end of guidance, down 6% from $59.2M in Q1 2025.
Definitive Healthcare terminates nominating agreement with Spectrum; designee resigned
Spectrum had right to designate one director nominee while holding ≥5% of outstanding shares.
Definitive Healthcare director Jeff Haywood resigns from Board and Compensation Committee
Jeff Haywood resigned from the Board and Compensation Committee effective March 30, 2026.
Q4 revenue $61.5M vs $62.3M prior year; adjusted EBITDA $18.0M (29% margin) vs $17.5M (28%).
Definitive Healthcare Q3 revenue $60M (-4% YoY); net loss $17.8M; raises FY revenue guidance low end
Revenue $60.0M (-4% vs $62.7M in Q3 2024); net loss $17.8M (vs $187.8M including $228.2M goodwill impairment).
Definitive Healthcare Q2 revenue $60.8M (-5% YoY); raises FY revenue guidance bottom by $3M
Q2 net loss $(9.3)M vs $(306.2)M (prior year included $363.6M goodwill impairment).
Jill Larsen resigned from the Board and as Chair of the Human Capital Management and Compensation Committee effective July 21, 2025.
Definitive Healthcare eliminates COO role; Shamsuddin Jensen to depart Aug 1, 2025
COO position eliminated; Kate Shamsuddin Jensen will remain employed through August 1, 2025.
Definitive Healthcare stockholders elect three Class I directors, ratify auditor, approve say-on-pay
Kevin Coop, Jason Krantz, and Lauren Young elected Class I directors with 118M, 117M, and 108M votes for, respectively.
Revenue $59.2M, down 7% YoY; net loss $155.1M including $176.5M goodwill impairment.
Definitive Healthcare Q4 revenue $62.3M (-6% YoY); guides FY2025 $230-240M; names Casey Heller CFO
Q4 revenue $62.3M, -6% YoY; net loss $(84.7)M including $97.1M goodwill impairment.
Definitive Healthcare enters $175M term loan and $50M revolver, maturing Jan 2030
New $175M term loan facility and $50M revolving credit facility with Bank of America as agent; matures January 16, 2030.
Q3 revenue $62.7M, down 4% YoY; net loss $(187.8)M includes $228.2M goodwill impairment; adjusted EBITDA $20.6M (33% margin).
Definitive Healthcare promotes Kate Shamsuddin Jensen to COO effective Oct 1
Ms. Shamsuddin Jensen, previously Chief Strategy Officer, named Chief Operating Officer.
Definitive Healthcare Q2 revenue $63.7M (+5% YoY); net loss $(306.2)M on $363.6M goodwill impairment
Revenue $63.7M (+5% YoY); net loss $(306.2)M including $363.6M goodwill impairment (up 2,538% from $(11.6)M).
Definitive Healthcare Q2 prelim revenue $63.7M (+5% YoY), goodwill impairment $363.6M; CRO resigns
Revenue $63.7M (+5% YoY); adjusted EBITDA $20.9M (33% margin) vs $17.2M (28%) YoY.
Definitive Healthcare grants CEO Kevin Coop 186,192 RSUs as make-whole award
RSU award granted July 4, 2024 to compensate for equity grant shortfall due to share price volatility.
Appoints Kevin Coop as CEO effective June 24; Founder Krantz remains Executive Chairman
Kevin Coop appointed CEO effective June 24, 2024; founder Jason Krantz steps down as interim CEO but stays as Executive Chairman.
Definitive Healthcare Q1 revenue $63.5M (+7% YoY); Adj. EBITDA margin 32%; $20M buyback
Revenue $63.5M, +7% YoY from $59.2M; net loss narrowed to $12.7M from $16.0M.
Q4 revenue $65.9M (+9% YoY); FY23 revenue $251.4M (+13% YoY).
CEO Robert Musslewhite resigned effective Jan 16, 2024; departure is without cause; receives 15 months accelerated vesting and up to $15K in legal fees.
Definitive Healthcare cuts 154 jobs, expects $6.5M-$7.2M restructuring charges
Workforce reduced by 154 employees as part of restructuring plan announced Jan 3, 2024.
Definitive Healthcare adopts executive severance plan with up to 9 months of benefits
Eligible employees get 9 months salary continuation (tenured ≥2 yrs) or 6 months (<2 yrs).
Definitive Healthcare Q3 revenue $65.3M (+14% YoY); net loss widens to $248.7M on non-cash charges
Revenue $65.3M, up 14% YoY from $57.4M; above high-end of guidance.
Definitive Healthcare names Carrie Lazorchak as CRO; Mirisola to depart Dec 31
CRO Joe Mirisola resigns effective Nov 1, 2023; remains Senior Advisor through Dec 31, 2023.
Definitive Healthcare appoints former Verisk CEO Scott Stephenson to board; Chris Mitchell resigns
Chris Mitchell (Spectrum Equity) resigned from board effective Sept 6, 2023; not due to any disagreement.
Definitive Healthcare Q2 revenue $61M (+12% YoY), acquires Populi; guides Q3 rev $63-64.5M
Revenue $61.0M (+12% YoY); net loss widened to $11.6M from $10.1M; adjusted EBITDA $17.2M (28% of revenue).
Restates 2020-2022 and Q1 2023 financials over sales tax; expects G&A expense increase of $6.8M-$10.2M.
Definitive Healthcare CRO Joseph Mirisola resigns; transition through Dec 31, 2023
Joseph Mirisola notified board of intent to resign as Chief Revenue Officer on June 8, 2023.
Chris Egan, Samuel Hamood, Jill Larsen, Sastry Chilukuri elected as Class II directors with >130M votes each.
Definitive Healthcare Q1 revenue $59.2M (+18% YoY); net loss $15.6M
Revenue $59.2M (+18% YoY from $50.1M); net loss $15.6M vs $13.1M prior year.
Definitive Healthcare Q4 revenue up 31% to $60.6M; FY23 guidance implies 14% growth
Q4 revenue $60.6M (+31% YoY); GAAP net income $6.7M vs loss $14.8M in Q4 2021.
Definitive Healthcare cuts ~6% of staff (55 employees) under restructuring plan
Reduction of approx. 55 employees (~6% of workforce) announced Jan 12, 2023.
Revenue $57.4M (+33% YoY), net loss $6.4M vs $21.0M; adjusted EBITDA $16.4M (29% revenue).
Definitive Healthcare appoints Sastry Chilukuri to board; Randy Winn departs
Sastry Chilukuri, co-CEO of Medidata, joins board and audit committee effective Sept 30, 2022.
Definitive Healthcare Q2 revenue $54.5M (+37% YoY); net loss narrows; raises FY guidance
Revenue $54.5M (+37% YoY); net loss ($9.6M) improved from ($15.0M) in Q2 2021.
Definitive Healthcare stockholders elect three Class I directors, ratify Deloitte as auditor
Jason Krantz, Chris Mitchell, Lauren Young elected as Class I directors with ~141.8M, ~134.7M, ~132.6M votes for respectively.
Definitive Healthcare Q1 revenue $50.1M (+36% YoY); CEO transition to Musslewhite in August
Revenue $50.1M, +36% YoY; net loss ($13.1M) widened from ($10.5M); adjusted net income $7.7M (vs $2.6M).
Definitive Healthcare Q4 revenue up 38% to $46.3M; acquires Analytical Wizards for $65M
Q4 revenue $46.3M (+38% YoY); GAAP net loss $14.8M, adjusted net income $6.6M.
Definitive Healthcare enters stock/unit purchase agreement with selling securityholders
Agreement dated Nov 10, 2021 to purchase a portion of Class A common stock and/or AIDH TopCo LLC units from certain Sellers.
Definitive Healthcare Q3 revenue up 43% to $43.1M; GAAP net loss widens to $21M
Revenue $43.1M (+43% YoY); adjusted EBITDA $14.4M (33% margin) vs $14.5M (48% margin) a year ago.
Definitive Healthcare appoints former OptumInsight CEO Robert Musslewhite as President
Robert Musslewhite appointed President, a newly created role, effective Oct 7, 2021; he had been a board member since June 2021.
Definitive Healthcare appoints former ADP CFO Kathleen Winters to board
Kathleen A. Winters elected to board of directors and Audit Committee, effective Oct 1, 2021.
Definitive Healthcare closes IPO of 17.9M shares at $27, raising ~$483M
Closed IPO of 17,888,888 shares (includes overallotment) at $27.00/share, gross proceeds ~$483M.
The Company previously announced that Richard Booth, the Company’s current CFO, would be departing the Company effective June 1, 2025.
On February 24, 2025, the Board of Directors (the “Board”) of the Company appointed Casey Heller to the position of Chief Financial Officer (“CFO”) effective June 2, 2025.
Richard Booth, the Company’s Chief Financial Officer, and the Company agreed that Mr. Booth will be leaving the Company effective June 1, 2025.
On September 29, 2024, the Board of Directors (the “Board”) of Definitive Healthcare Corp. (the “Company”) promoted Kate Shamsuddin Jensen, the Company’s current Chief Strategy Officer, to the role of Chief Operating Officer, effective as of October 1, 2024 (the “Effective Date”).
On July 24, 2024, Carrie Lazorchak, the Chief Revenue Officer of the Company, provided the Company with notice of her resignation, effective August 2, 2024.
On May 20, 2024, the Board of Directors (the “Board”) of Definitive Healthcare Corp. (the “Company”) appointed Kevin Coop to the position of Chief Executive Officer (“CEO”) and as a member of the Board, each effective June 24, 2024 (the “Start Date”).
Effective on the Start Date, Jason Krantz, the Company’s founder, Executive Chairman of the Board and current Interim CEO will step down from his role as Interim CEO and continue to serve as Executive Chairman of the Board.
On January 12, 2024, the Company’s Board of Directors appointed Jason Krantz, the Company’s founder and Executive Chairman, as Interim Chief Executive Officer, effective January 16, 2024.
On January 16, 2024, the Company announced that Robert Musslewhite has stepped down as the Company’s Chief Executive Officer and as a member of the Company’s Board of Directors, effective January 16, 2024
In addition, Mr. Mirisola will cease to be Chief Revenue Officer effective November 1, 2023 and will, at such time, become a Senior Advisor.
Following Mr. Mitchell’s resignation, on September 6, 2023, the Board appointed Scott Stephenson as a member of the Board and as a member of the Nominating and Corporate Governance Committee of the Board.
On September 6, 2023, Chris Mitchell resigned from the Board of Directors (the “Board”) of Definitive Healthcare Corp. (the “Company”), which resignation became effective upon the appointment of Scott Stephenson as a member of the Board on September 6, 2023.
Max materiality 0.90 · Median 0.65 · Most common event earnings